Pre-made Mavrilimumab benchmark antibody ( Whole mAb, anti-CSF2RA therapeutic antibody, Anti-GMR/CD116/CSF2R/SMDP4/CDw116GMR-alpha/GMCSFR-alpha/GM-CSF-R-alpha Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Mavrilimumab biosimilar, Whole mAb, Anti-CSF2RA Antibody: Anti-GMR/CD116/CSF2R/SMDP4/CDw116GMR-alpha/GMCSFR-alpha/GM-CSF-R-alpha therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).
| Products Name (INN Index) | Pre-Made Mavrilimumab biosimilar, Whole mAb, Anti-CSF2RA Antibody: Anti-GMR/CD116/CSF2R/SMDP4/CDw116GMR-alpha/GMCSFR-alpha/GM-CSF-R-alpha therapeutic antibody |
|---|---|
| INN Name | Mavrilimumab |
| Target | CSF2RA |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2009 |
| Year Recommended | 2010 |
| Companies | Zenyth Therapeutics Kiniksa Pharmaceuticals,MedImmune |
| Conditions Approved | NA |
| Conditions Active | Giant cell arteritis,COVID-19,Inflammation |
| Conditions Discontinued | Rheumatoid arthritis |
| Development Tech | CAT Phage Display |
| Previous Name | favezelimab |
| Gm Offical Target Name | CSF2RA |
| Package |
